BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Maxwell Biosciences

1 post

Maxwell Biosciences, founded in 2016, is a preclinical-stage drug platform firm that is actively developing an all-new CLAROMER™ biotechnology platform that creates proprietary, virucidal, smaller molecule, non-peptide chemicals known as peptoids.

This novel biotechnology emulates the power and flexibility of natural antimicrobial peptides while delivering pharmacological benefits of a small molecule. The organization is led by a group of distinguished scientists and executives.

U.S. government-funded labs recently confirmed that a study evaluating the virucidal activity of Maxwell’s lead drug candidate has shown direct virucidal efficacy against SARS-CoV-2.

Maxwell’s drugs appear to have a wide therapeutic window in humans, according to recent live mouse safety data from Texas A&M.

Before this, Maxwell’s drugs have been found to show direct activity against the structure of the Herpes Simplex Virus (HSV-1).

Maxwell Pharmaceuticals, Inc.’s drug platform is bolstered by a granted patent portfolio that gives it a significant advantage in the fight against emerging viral pandemics.

The Future of Genomics: GeneDx (WGS) Achieves Profitability & Expands Market Reach

Biotech NewsMaxwell Biosciences, Makers of CLAROMER, Hire John Lord, Ph.D., as VP of Research and Development

  • BioTech Health X
  • May 6, 2021
Austin, Texas based biotechnology company Maxwell Biosciences have announced the hiring of Dr. John Lord as Vice President…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • 10 Healthcare and Insurance Stocks to Buy as Democrats Take Control
  • 5 Healthcare and Insurance Stocks to Buy as Democrats Take Control
  • Johnson & Johnson (JNJ) Flexes Its Oncology Muscle With 16.4% Sales Growth
  • Would You Still Dare to Invest in Revolution Medicines (RVMD)?
  • Merck (MRK) Has an $8.6 Billion Cancer Franchise and a Succession Plan to Prove
Featured Posts
    • November 11, 2026
    10 Healthcare and Insurance Stocks to Buy as Democrats Take Control
    • November 11, 2026
    5 Healthcare and Insurance Stocks to Buy as Democrats Take Control
    • November 6, 2026
    Johnson & Johnson (JNJ) Flexes Its Oncology Muscle With 16.4% Sales Growth
    • November 6, 2026
    Would You Still Dare to Invest in Revolution Medicines (RVMD)?
    • November 6, 2026
    Merck (MRK) Has an $8.6 Billion Cancer Franchise and a Succession Plan to Prove
Recent Posts
  • AbbVie (ABBV) Delivers $17.4 Billion in Revenue
    • November 6, 2026
  • Pfizer (PFE) Gets an Oncology Boost as Padcev Sales Surge 55%
    • November 6, 2026
  • Guardant Health (GH) Posts 44% Revenue Growth as Liquid Biopsy Gains Ground
    • November 6, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (6)
  • Biotech News (1,187)
  • Uncategorized (2)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top